Terumo Neuro
Robert Gash is a seasoned professional with extensive experience in clinical research and operations, currently serving as Sr. Director at MicroVention-Terumo, where responsibilities include enhancing the clinical research department and overseeing clinical studies across the US and China. With a strong background at Terumo Medical Corporation where the clinical research team expanded significantly, Gash has implemented quality assurance initiatives and overseen clinical strategies at Covidien and Novartis. Previous roles at Johnson & Johnson and STERIS Corporation provided foundational experiences in managing clinical trials, vendor selection, and regulatory compliance. Gash holds a Bachelor's degree in Biology and Sports Medicine from the University of Mount Union and is pursuing a Master's degree in Clinical Research Administration at Walden University.
This person is not in any offices
Terumo Neuro
1 followers
A global leader in neurovascular innovation, MicroVention is now Terumo Neuro. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care. We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica.